SEC Form 10-K filed by Whitehawk Therapeutics Inc.
$WHWK
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/5/2026 | $6.00 | Outperform | Oppenheimer |
Oppenheimer initiated coverage of Whitehawk Therapeutics with a rating of Outperform and set a new price target of $6.00
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platformTumor regressions observed across various cancer models at low single‑digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC)Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026MORRISTOWN, N.J., April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug c
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.About Whitehawk TherapeuticsWhitehawk Therapeutic
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancerFindings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being explored in Phase 1 for advanced ovarian and endometrial cancersMORRISTOWN, N.J., April 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-wor
S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
10-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy. "I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and